The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients;Az LRRK2 gyakori G2019S-mutációjának hiánya 120, korai kezdetu magyar Parkinson-beteg esetében

Ideggyogyaszati Szemle

Volumn 65, Issue 7-8, 2012, Pages 239-242

  Balicza, Péter ^a   Bereznai, Benjamin ^a   Takáts, Annamária ^a   Klivényi, Péter ^b   Dibó, György ^b   Hidasi, Eszter ^c   Balogh, István ^c   Molnár, Mária Judit ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Common mutation; Gen test; Genetics; LRRK2; Parkinson disease

Indexed keywords

LEUCINE RICH REPEAT KINASE 2;

ARTICLE; GENE MUTATION; HUMAN; HUNGARY; PARKINSON DISEASE; SUBSTITUTION REACTION;

ADULT; AGE OF ONSET; AGED; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GLYCINE; HUMANS; HUNGARY; MALE; MIDDLE AGED; PARKINSON DISEASE; POINT MUTATION; PROTEIN-SERINE-THREONINE KINASES; SERINE;

EID: 84865469159     PISSN: 00191442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Tanner CM, Aston DA. Epidemiology of Parkinson's disease and akinetic syndromes. Curr Opin Neurol 2000;13(4):427-30.
2. de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S21-3.
3. Allam MF, Del Castillo AS, Navajas RF. Parkinson's disease risk factors: genetic, environmental, or both? Neurol Res 2005;27(2):206-8.
4. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59.
5. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002;51(3):296-301.
6. Klein C, Schneider SA, Lang AE. Hereditary parkinsonism: Parkinson disease look-alikes - an algorithm for clinicians to "PARK" genes and beyond. Mov Disord 2009;24(14):2042-58.
7. Healy DG, Falchi M, O'Sullivan SS et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7(7):583-90.
8. Kay DM, Zabetian CP, Factor SA et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006;21(4):519-23.
9. Molnar MJ, Bencsik P. Establishing a neurological-psychiatric biobank: banking, informatics, ethics. Cell Immunol 2006;244(2):101-4.
10. Zimprich A, Biskup S, Leitner P et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44(4):601-7.
11. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009;18(R1):R48-59.
12. Alcalay RN, Caccappolo E, Mejia-Santana H et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010;67(9):1116-22.
13. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010;16(4):237-42.
14. Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm 2009;116(11):1473-82.
15. Clarimón J, Pagonabarraga J, Paisán-Ruíz C et al. Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening. Mov Disord 2008;23(4):518-23.
16. Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK. LRRK2 gene and tremor-dominant parkinsonism. Arch Neurol 2006;63(9):1346-7.
17. Lücking CB, Dürr A, Bonifati V et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000;342(21):1560-7.
18. von Coelln R, Dawson VL, Dawson TM. Parkin-associated Parkinson's disease. Cell Tissue Res 2004;318(1):175-84.
19. Di Napoli M, Shah IM, Stewart DA. Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside. Expert Rev Neurother 2007;7(12):1693-729.
20. West AB, Moore DJ, Biskup S et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005;102(46):16842-7.
21. Lin X, Parisiadou L, Gu XL et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009;64(6):807-27.